100 related articles for article (PubMed ID: 16784849)
21. Knockdown of ATP8B1 expression leads to specific downregulation of the bile acid sensor FXR in HepG2 cells: effect of the FXR agonist GW4064.
Martínez-Fernández P; Hierro L; Jara P; Alvarez L
Am J Physiol Gastrointest Liver Physiol; 2009 May; 296(5):G1119-29. PubMed ID: 19228886
[TBL] [Abstract][Full Text] [Related]
22. Human UDP-glucuronosyltransferase (UGT)1A3 enzyme conjugates chenodeoxycholic acid in the liver.
Trottier J; Verreault M; Grepper S; Monté D; Bélanger J; Kaeding J; Caron P; Inaba TT; Barbier O
Hepatology; 2006 Nov; 44(5):1158-70. PubMed ID: 17058234
[TBL] [Abstract][Full Text] [Related]
23. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia.
Evans MJ; Mahaney PE; Borges-Marcucci L; Lai K; Wang S; Krueger JA; Gardell SJ; Huard C; Martinez R; Vlasuk GP; Harnish DC
Am J Physiol Gastrointest Liver Physiol; 2009 Mar; 296(3):G543-52. PubMed ID: 19136377
[TBL] [Abstract][Full Text] [Related]
24. 3D-QSAR studies with the aid of molecular docking for a series of non-steroidal FXR agonists.
Zhang T; Zhou JH; Shi LW; Zhu RX; Chen MB
Bioorg Med Chem Lett; 2007 Apr; 17(8):2156-60. PubMed ID: 17307356
[TBL] [Abstract][Full Text] [Related]
25. FXR-mediated regulation of angiotensin type 2 receptor expression in vascular smooth muscle cells.
Zhang Q; He F; Kuruba R; Gao X; Wilson A; Li J; Billiar TR; Pitt BR; Xie W; Li S
Cardiovasc Res; 2008 Feb; 77(3):560-9. PubMed ID: 18006431
[TBL] [Abstract][Full Text] [Related]
26. Bile acid-stimulated expression of the farnesoid X receptor enhances the immune response in Barrett esophagus.
Capello A; Moons LM; Van de Winkel A; Siersema PD; van Dekken H; Kuipers EJ; Kusters JG
Am J Gastroenterol; 2008 Jun; 103(6):1510-6. PubMed ID: 18510604
[TBL] [Abstract][Full Text] [Related]
27. Thyroid receptor ligands. Part 7: Indirect antagonists of the thyroid hormone receptor with improved affinity.
Malm J; Gordon S; Brandt P; Carlsson B; Agback P; Bäckbro Saeidi A; Sandberg J
Bioorg Med Chem Lett; 2007 Apr; 17(7):2018-21. PubMed ID: 17254783
[TBL] [Abstract][Full Text] [Related]
28. Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy.
Van Mil SW; Milona A; Dixon PH; Mullenbach R; Geenes VL; Chambers J; Shevchuk V; Moore GE; Lammert F; Glantz AG; Mattsson LA; Whittaker J; Parker MG; White R; Williamson C
Gastroenterology; 2007 Aug; 133(2):507-16. PubMed ID: 17681172
[TBL] [Abstract][Full Text] [Related]
29. An efficient synthesis and biological study of novel indolyl-1,3,4-oxadiazoles as potent anticancer agents.
Kumar D; Sundaree S; Johnson EO; Shah K
Bioorg Med Chem Lett; 2009 Aug; 19(15):4492-4. PubMed ID: 19559607
[TBL] [Abstract][Full Text] [Related]
30. Dithiocarbamic acid esters as anticancer agent. Part 1: 4-substituted-piperazine-1-carbodithioic acid 3-cyano-3,3-diphenyl-propyl esters.
Hou X; Ge Z; Wang T; Guo W; Cui J; Cheng T; Lai C; Li R
Bioorg Med Chem Lett; 2006 Aug; 16(16):4214-9. PubMed ID: 16766185
[TBL] [Abstract][Full Text] [Related]
31. Role of bile acids and bile acid receptors in metabolic regulation.
Lefebvre P; Cariou B; Lien F; Kuipers F; Staels B
Physiol Rev; 2009 Jan; 89(1):147-91. PubMed ID: 19126757
[TBL] [Abstract][Full Text] [Related]
32. Computationally identified novel diphenyl- and phenylpyridine androgen receptor antagonist structures.
Söderholm AA; Viiliäinen J; Lehtovuori PT; Eskelinen H; Roell D; Baniahmad A; Nyrönen TH
J Chem Inf Model; 2008 Sep; 48(9):1882-90. PubMed ID: 18712859
[TBL] [Abstract][Full Text] [Related]
33. Farnesoid X receptor: from structure to potential clinical applications.
Pellicciari R; Costantino G; Fiorucci S
J Med Chem; 2005 Aug; 48(17):5383-403. PubMed ID: 16107136
[No Abstract] [Full Text] [Related]
34. Peroxisome proliferator-activated receptor gamma-independent suppression of androgen receptor expression by troglitazone mechanism and pharmacologic exploitation.
Yang CC; Wang YC; Wei S; Lin LF; Chen CS; Lee CC; Lin CC; Chen CS
Cancer Res; 2007 Apr; 67(7):3229-38. PubMed ID: 17409431
[TBL] [Abstract][Full Text] [Related]
35. Molecular dynamics simulations of human LRH-1: the impact of ligand binding in a constitutively active nuclear receptor.
Burendahl S; Treuter E; Nilsson L
Biochemistry; 2008 May; 47(18):5205-15. PubMed ID: 18410128
[TBL] [Abstract][Full Text] [Related]
36. FXR: a metabolic regulator and cell protector.
Wang YD; Chen WD; Moore DD; Huang W
Cell Res; 2008 Nov; 18(11):1087-95. PubMed ID: 18825165
[TBL] [Abstract][Full Text] [Related]
37. Bile acids, farnesoid X receptor, atherosclerosis and metabolic control.
Kuipers F; Stroeve JH; Caron S; Staels B
Curr Opin Lipidol; 2007 Jun; 18(3):289-97. PubMed ID: 17495603
[TBL] [Abstract][Full Text] [Related]
38. Effects of coumestrol on lipid and glucose metabolism as a farnesoid X receptor ligand.
Takahashi M; Kanayama T; Yashiro T; Kondo H; Murase T; Hase T; Tokimitsu I; Nishikawa J; Sato R
Biochem Biophys Res Commun; 2008 Aug; 372(3):395-9. PubMed ID: 18457666
[TBL] [Abstract][Full Text] [Related]
39. Scalarane sesterterpenes from a marine sponge of the genus Spongia and their FXR antagonistic activity.
Nam SJ; Ko H; Ju MK; Hwang H; Chin J; Ham J; Lee B; Lee J; Won DH; Choi H; Ko J; Shin K; Oh T; Kim S; Rho JR; Kang H
J Nat Prod; 2007 Nov; 70(11):1691-5. PubMed ID: 17988093
[TBL] [Abstract][Full Text] [Related]
40. Discovery of sulfated sterols from marine invertebrates as a new class of marine natural antagonists of farnesoid-X-receptor.
Sepe V; Bifulco G; Renga B; D'Amore C; Fiorucci S; Zampella A
J Med Chem; 2011 Mar; 54(5):1314-20. PubMed ID: 21309576
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
